PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1
inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed
or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction
therapy.